Savara’s (SVRA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Savara (NASDAQ:SVRA) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright also issued estimates for Savara’s Q1 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

A number of other equities analysts have also recently issued reports on SVRA. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company started coverage on shares of Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Price Performance

Savara stock opened at $2.91 on Friday. The stock’s 50 day moving average is $2.72 and its 200 day moving average is $3.25. Savara has a one year low of $2.26 and a one year high of $5.34. The firm has a market cap of $499.41 million, a P/E ratio of -6.77 and a beta of 0.60. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. As a group, research analysts expect that Savara will post -0.45 EPS for the current year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently made changes to their positions in SVRA. Frazier Life Sciences Management L.P. grew its position in Savara by 6.2% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 8,660,379 shares of the company’s stock worth $26,587,000 after purchasing an additional 502,994 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company’s stock worth $482,000 after buying an additional 31,168 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Savara by 16.6% in the fourth quarter. Woodline Partners LP now owns 2,686,938 shares of the company’s stock valued at $8,249,000 after acquiring an additional 381,743 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Savara by 33.2% during the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock valued at $33,079,000 after acquiring an additional 2,685,000 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Savara by 178.1% during the fourth quarter. Squarepoint Ops LLC now owns 122,635 shares of the company’s stock worth $376,000 after acquiring an additional 78,540 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.